FDA Chief Scientist Jesse Goodman, who developed the agency’s Medical Countermeasure Initiative, will be leaving his post to “return to academia and clinical medicine,” FDA Commissioner Margaret Hamburg said Jan. 9. Goodman has been at FDA since 1998, and previously served as director of the Center for Biologics Evaluation and Research. In 2009, he coordinated the agency’s response to the 2009 swine flu pandemic. (See Also see "First Showing Of New FDA Leadership Comes In Public Health Emergency" - Medtech Insight, 4 May, 2009..)
Goodman is leaving to become a professor of medicine and infectious diseases and an attending physician at Georgetown University and...
Welcome to Medtech Insight
Create an account to read this article
Already a subscriber?